Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism

Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism

Objective: SGLT2 inhibitors increase urinary glucose excretion and have beneficial effects on cardiovascular and renal outcomes; the underlying mechanism may be metabolic adaptations due to urinary glucose loss. Here, we investigated the cellular and molecular effects of 5 weeks of dapagliflozin tre...

Full description

Bibliographic Details
Main Authors: Yvo J.M. op den Kamp, Anne Gemmink, Marlies de Ligt, Bas Dautzenberg, Esther Kornips, Johanna A. Jorgensen, Gert Schaart, Russell Esterline, Diego A. Pava, Joris Hoeks, Vera B. Schrauwen-Hinderling, Sander Kersten, Bas Havekes, Timothy R. Koves, Deborah M. Muoio, Matthijs K.C. Hesselink, Jan Oscarsson, Esther Phielix, Patrick Schrauwen
Format: Article
Language:English
Published: Elsevier 2022-12-01
Series:Molecular Metabolism
Subjects:
Acylcarnitines
Dapagliflozin
Myocellular lipid metabolism
Mitochondrial function
SGLT2i
TCA cycle Intermediates
Online Access:http://www.sciencedirect.com/science/article/pii/S2212877822001892

Similar Items

Similar Items